Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: A comparative interview study

Psychological Medicine

Volumn 46, Issue 10, 2016, Pages 2179-2188

  Jung, E ^a   Wiesjahn, M ^a   Wendt, H ^b   Bock, T ^c   Rief, W ^a   Lincoln, T M ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic medication; coping; functioning; non medicated patients; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; COMPARATIVE STUDY; COPING BEHAVIOR; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL INTERVIEW; SCHIZOPHRENIA; SOCIAL SUPPORT;

ADAPTATION, PSYCHOLOGICAL; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; SCHIZOPHRENIA; SOCIAL SUPPORT;

EID: 84973397946     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716000775     Document Type: Article

References (44)

1. Ascher-Svanum H, Faries D, Zhu B, Ernst FR, Swartz MS, Swanson JW (2006). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67, 453-460
2. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology (2011). Evidencebased guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England) 25, 567-620
3. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT) (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 71-93
4. Cohen J (1992). Statistical power analysis. Current Directions in Psychological Science 1, 98-101
5. Connor KM, Davidson JRT (2003). Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depression and Anxiety 18, 76-82
6. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105, 175-187
7. Erickson DH, Beiser M, Iacono WG (1998). Social support predicts 5-year outcome in first-episode schizophrenia. Journal of Abnormal Psychology 107, 681-685
8. Fahrenberg J, Myrtek M, Pawlik K, Perrez M (2007). Ambulatory assessment-monitoring behavior in daily life settings a behavioral-scientific challenge for psychology. European Journal of Psychological Assessment 23, 206-213
9. Field A (2009). Discovering Statistics using SPSS, 2nd edn. Sage: London
10. Fydrich T, Sommer G, Tydecks S, Brähler E (2009). Fragebogen zur sozialen Unterstützung (F-SozU): Normierung der Kurzform (K-14) [Social Support Questionnaire (F-SozU): standardization of short form (K-14)]. Zeitschrift Für Medizienische Psychologie 18, 43-48
11. Goodman SH, Sewell DR, Cooley EL, Leavitt N (1993). Assessing levels of adaptive functioning: the Role Functioning Scale. Community Mental Health Journal 29, 119-131
12. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube CK, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PWH, Leòn CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001). Recovery from psychotic illness a 15-and 25-year international follow-up study. British Journal of Psychiatry : The Journal of Mental Science 178, 506-517
13. Harrow M, Jobe TH (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications a 15-year multifollow-up study. Journal of Nervous and Mental Disease 195, 406-414
14. Harrow M, Jobe TH (2013). Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophrenia Bulletin 39, 962-965
15. Harrow M, Jobe TH, Faull RN (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychological Medicine 42, 2145-2155
16. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011). Long-term antipsychotic treatment and brain volumes. Archives of General Psychiatry 68, 128-137
17. Konings M, Bak M, Hanssen M, van Os J, Krabbendam L (2006). Validity and reliability of the CAPE a self-report instrument for themeasurement ofpsychotic experiences inthe general population. Acta Psychiatrica Scandinavica 114, 55-61
18. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002). Prevalence of and risk for medication nonadherence in patients with schizophrenia a comprehensive review of recent literature. Journal of Clinical Psychiatry 63, 892-909
19. Lee PW, Lieh-Mak F, Yu KK, Spinks JA (1993). Coping strategies of schizophrenic patients and their relationship to outcome. British Journal of Psychiatry 163, 177-182
20. Leucht S, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68
21. Leucht S, Engel R, Davis J (2009). How effective are secondgeneration antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 14, 429-447
22. Leucht S, Tardy M, Komossa K, Heres S, KisslingW, Salanti G, Davis JM (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia a systematic review and meta-analysis. Lancet 379, 2063-2071
23. Lewander T (1994). Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scandinavica. Supplementum 380, 8-13
24. Lieberman J, Stroup T, McEvoy J, Schwartz M, Rosenheck R, Perkins D, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao J (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223
25. LincolnTM,PeterN,SchäferM,MoritzS(2009). Impactof stress on paranoia an experimental investigation ofmoderators and mediators. PsychologicalMedicine 39, 1129-1139
26. Lincoln TM, Ziegler M, Mehl S, Kesting ML, Lüllmann E, Westermann S, Rief W (2012). Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis a randomized clinical practice trial. Journal of Consulting and Clinical Psychology 80, 674-686
27. McNally SE, Goldberg JO (1997). Natural cognitive coping strategies in schizophrenia. British Journal of Medical Psychology 70, 159-167
28. Moilanen J, Haapea M, Miettunen J, Jääskeläinen E, Veijola J, Isohanni M, Koponen H (2013). Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication-A 10-year follow-up of the Northern Finland 1966 Birth Cohort study. European Psychiatry 28, 53-58
29. Moritz S, Hünsche A, Lincoln TM (2014). Nonadherence to antipsychotics in schizophrenia: the role of positive attitudes towards positive symptoms. European Neuropsychopharmacology 24, 1745-1752
30. Newcomer JW (2007). Antipsychotic medications:metabolic and cardiovascular risk. Journal of Clinical Psychiatry 68, 8-13
31. Newcomer JW, Haupt DW (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 51, 480-491
32. Norman RMG, Malla AK, Manchanda R, Harricharan R, Takhar J, Northcott S (2005). Social support and three-year symptom and admission outcomes for first episode psychosis. Schizophrenia Research 80, 227-234
33. Phillips LJ, Francey SM, Edwards J, McMurray N (2009). Strategies used by psychotic individuals to cope with life stress and symptoms of illness a systematic review. Anxiety, Stress and Coping 22, 371-410
34. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360, 225-235
35. Rückl S, Büche L, Gentner NC, Heyne J, Von Bock A, Barthel A, Vedder H, Bürgy M, Kronmüller KT (2012). Heidelberg Coping Scales for Delusions: psychometric evaluation of an expert rating instrument. Psychopathology 45, 244-251
36. Sass H, Wittchen HU, Zaudig M, Houben I (2003). Diagnostisches und Statistisches Manual Psychischer Störungen (DSM-IV-TR) [Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)]. Hogrefe: Göttingen
37. Schwartz RC (2007). Concurrent validity of the Global Assessment of Functioning Scale for clients with schizophrenia. Psychological Reports 100, 571-574
38. Torgalsboern A-K (2012). Sustaining full recover in schizophrenia after 15 years: does resilience matter? Clinical Schizophrenia and Related Psychoses 5, 193-200
39. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, TohenM (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry 54, 49-55
40. Weiden PJ, Miller AL (2001). Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. Journal of Psychiatric Practice 7, 41-47
41. Whitaker R (2004). The case against antipsychotic drugs a 50-year record of doing more harm than good. Medical Hypotheses 62, 5-13
42. Wiesjahn M, Jung E, Lamster F, Rief W, Lincoln TM (2014). Explaining attitudes and adherence to antipsychotic medication: the development of a process model. Schizophrenia Research and Treatment 2014, 341545
43. Wittchen HU, Zaudig M, Fydrich T (1997). Strukturiertes Klinisches Interview für DSM-IV [Structured Clinical Interview for DSM-IV]. Hogrefe: Göttingen
44. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/ discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70, 913-920